MarginsXMarginsX
Home › Markets › Health Care › CTOR

Citius Oncology Inc. (CTOR)

CTOR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.5350
-6.76% on the day
Market cap
$49.7M
Nano cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerCTOR on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2022
SEC CIK0001851484

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
13.9 months
$16.6M cash at June 30, 2026
Share count, 1 year
+18.6%
2025-08-11 to 2026-08-13 · +939.9% over 3 years
Going-concern doubt
Yes
10-Q filed August 14, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"We will need to raise additional capital to support our operations beyond November 2026, which raises substantial doubt about our ability to continue as a going concern within one year after the date that the accompanying financial statements are issued."
10-Q 2026-08-14
Cash and burn$16.6M cash; operating cash flow -$3.6M a quarter.Report 2026-06-30
Shares outstanding92,981,204 (2026-08-13); 78,370,584 a year earlier; 8,941,000 three years earlier.Cover page 2026-08-13
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2025-12-10
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2026-04-28
AuditorWolf & Company, P.C., Boston, Massachusetts, United StatesPCAOB Form AP 2026-01-27
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-06-30
$1.5M-$8.9M-$2.7M$16.6MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q2 2026
2026-03-31
$1.7M-$26.6M-$3.8M$2.6MNo debt tagsNeeds four quarters10-Q 2026-05-15
Q1 2026
2025-12-31
$3.9M-$5.5M-$7.4M$7.3MNo debt tagsNeeds four quarters10-Q 2026-02-13
Q4 2025
2025-09-30
Not filed-$5.0MNot filed$3.9MNo debt tagsNeeds four quarters10-K 2025-12-23
Q3 2025
2025-06-30
Not filed-$5.4MNot filed$112No debt tagsNeeds four quarters10-Q 2026-08-14
Q2 2025
2025-03-31
Not filed-$7.7MNot filed$112No debt tagsNeeds four quarters10-Q 2026-08-14
Q1 2025
2024-12-31
Not filed-$6.7MNot filed$112No debt tagsNeeds four quarters10-Q 2026-08-14
Q4 2024
2024-09-30
Not filed-$6.8MNot filed$112No debt tagsNeeds four quarters10-K 2025-12-23

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.

Price moves

WindowReturn
1 week+12.5%
1 month-27.5%
3 months-30.6%
Year to date-42.6%
1 year-56.8%
From 52-week high-65.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
IBIOiBio Inc.$0.7067-3.42%$49.8M
RFLRafael Holdings Inc.$0.9701-9.34%$50.6M
MREOMereo BioPharma Group plc$0.3050-0.81%$48.7M
QUCYQuantum Cyber N.V.$0.5850-7.58%$51.0M
HOWLWerewolf Therapeutics Inc.$0.9908+1.07%$48.2M
SDEVStablecoin Development Corporation$0.7055-9.55%$51.6M
APLMApollomics Inc.$17.84+0.91%$51.7M
CLNNClene Inc.$3.66-6.63%$52.7M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier